Protalix BioTherapeutics – Consensus Indicates Potential 611.7% Upside

Broker Ratings

Protalix BioTherapeutics found using ticker (PLX) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 12.5 and 7 with the average target price sitting at 9.75. Given that the stocks previous close was at 1.37 this indicates there is a potential upside of 611.7%. The day 50 moving average is 1.46 and the 200 moving average now moves to 2.8. The market cap for the company is $60m. Company Website: http://www.protalix.com

Protalix BioTherapeutics, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index